Sana Biotechnology, Inc. (NASDAQ:SANA - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Sana Biotechnology in a research note issued on Tuesday, March 18th. HC Wainwright analyst E. Bodnar expects that the company will earn ($0.24) per share for the quarter. HC Wainwright has a "Buy" rating and a $11.00 price objective on the stock. The consensus estimate for Sana Biotechnology's current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Sana Biotechnology's Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.24) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.89) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at ($0.59) EPS.
Sana Biotechnology (NASDAQ:SANA - Get Free Report) last issued its earnings results on Monday, March 17th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02.
SANA has been the topic of several other research reports. Jefferies Financial Group assumed coverage on Sana Biotechnology in a research note on Friday, March 14th. They set a "buy" rating and a $7.00 target price on the stock. Citizens Jmp raised Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price objective for the company in a research note on Tuesday, March 18th. Finally, TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $10.80.
Read Our Latest Research Report on SANA
Sana Biotechnology Trading Up 4.8 %
Sana Biotechnology stock traded up $0.11 during trading on Thursday, reaching $2.42. The company had a trading volume of 2,319,241 shares, compared to its average volume of 3,057,021. The firm's 50-day simple moving average is $2.93 and its 200 day simple moving average is $3.11. The firm has a market capitalization of $544.56 million, a price-to-earnings ratio of -1.73 and a beta of 1.63. Sana Biotechnology has a 52 week low of $1.52 and a 52 week high of $10.50.
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the company. Cerity Partners LLC purchased a new stake in Sana Biotechnology in the fourth quarter valued at $25,000. Tower Research Capital LLC TRC lifted its position in shares of Sana Biotechnology by 229.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company's stock valued at $25,000 after acquiring an additional 10,548 shares in the last quarter. Syon Capital LLC acquired a new stake in Sana Biotechnology during the 4th quarter worth $27,000. Wilmington Savings Fund Society FSB purchased a new stake in Sana Biotechnology during the 3rd quarter valued at about $29,000. Finally, Ameriprise Financial Inc. purchased a new stake in shares of Sana Biotechnology in the fourth quarter valued at approximately $29,000. 88.23% of the stock is owned by institutional investors and hedge funds.
Insider Transactions at Sana Biotechnology
In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the business's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the sale, the insider now owns 4,541,511 shares of the company's stock, valued at approximately $29,474,406.39. The trade was a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 31.10% of the company's stock.
Sana Biotechnology Company Profile
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Further Reading
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
